Annual Cash & Cash Equivalents
$109.97 M
+$41.57 M+60.78%
31 December 2023
Summary:
Kymera Therapeutics annual cash & cash equivalents is currently $109.97 million, with the most recent change of +$41.57 million (+60.78%) on 31 December 2023. During the last 3 years, it has risen by +$78.96 million (+254.68%). KYMR annual cash & cash equivalents is now at all-time high.KYMR Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$110.72 M
+$43.11 M+63.75%
30 September 2024
Summary:
Kymera Therapeutics quarterly cash and cash equivalents is currently $110.72 million, with the most recent change of +$43.11 million (+63.75%) on 30 September 2024. Over the past year, it has increased by +$29.67 million (+36.60%). KYMR quarterly cash and cash equivalents is now -29.40% below its all-time high of $156.82 million, reached on 30 September 2021.KYMR Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
KYMR Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +60.8% | +36.6% |
| 3 y3 years | +254.7% | -29.4% |
| 5 y5 years | +166.5% | - |
KYMR Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +254.7% | -29.4% | +228.2% |
| 5 y | 5 years | at high | +254.7% | -29.4% | +257.1% |
| alltime | all time | at high | +254.7% | -29.4% | +257.1% |
Kymera Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $110.72 M(+63.8%) |
| June 2024 | - | $67.61 M(-27.7%) |
| Mar 2024 | - | $93.51 M(-15.0%) |
| Dec 2023 | $109.97 M(+60.8%) | $109.97 M(+35.7%) |
| Sept 2023 | - | $81.05 M(+54.7%) |
| June 2023 | - | $52.39 M(+4.5%) |
| Mar 2023 | - | $50.15 M(-26.7%) |
| Dec 2022 | $68.39 M | $68.39 M(-56.1%) |
| Sept 2022 | - | $155.66 M(+102.4%) |
| June 2022 | - | $76.91 M(+128.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | $33.73 M(-29.7%) |
| Dec 2021 | $47.98 M(+54.7%) | $47.98 M(-69.4%) |
| Sept 2021 | - | $156.82 M(+84.7%) |
| June 2021 | - | $84.90 M(+59.9%) |
| Mar 2021 | - | $53.10 M(+71.3%) |
| Dec 2020 | $31.00 M(-59.2%) | $31.00 M(-43.2%) |
| Sept 2020 | - | $54.59 M(-10.5%) |
| June 2020 | - | $60.97 M(-19.8%) |
| Dec 2019 | $76.02 M(+84.2%) | $76.02 M |
| Dec 2018 | $41.26 M | - |
FAQ
- What is Kymera Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Kymera Therapeutics?
- What is Kymera Therapeutics annual cash & cash equivalents year-on-year change?
- What is Kymera Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Kymera Therapeutics?
- What is Kymera Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Kymera Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of KYMR is $109.97 M
What is the all time high annual cash & cash equivalents for Kymera Therapeutics?
Kymera Therapeutics all-time high annual cash & cash equivalents is $109.97 M
What is Kymera Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, KYMR annual cash & cash equivalents has changed by +$41.57 M (+60.78%)
What is Kymera Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of KYMR is $110.72 M
What is the all time high quarterly cash and cash equivalents for Kymera Therapeutics?
Kymera Therapeutics all-time high quarterly cash and cash equivalents is $156.82 M
What is Kymera Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, KYMR quarterly cash and cash equivalents has changed by +$29.67 M (+36.60%)